Business
CAMP4 Appoints Michael MacLean to its Board of Directors
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  ( ...
About this update from Canadian Goldcamps Corp
[{"type":"text","content":"CAMP4 Appoints Michael MacLean to its Board of DirectorsAppointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder\nCAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company’s Board of Directors. “Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4’s Board,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “His experience guiding biotech companies through critical phases of growth will be invaluable as we advance CMP-002 toward the clinic. We look forward to drawing on his counsel as we work to bring a potential first-in-class, disease-modifying therapy to patients with SYNGAP1 who have no approved treatment options today.” Mr. MacLean added, “I am pleased to join the CAMP4 Board at such a pivotal moment in the Company’s journey. CAMP4 is doing meaningful, scientifically rigorous work with its regRNA-targeting platform, and I deeply believe in the advancement of CMP-002 for patients living with SYNGAP1-related disorder. Together with CAMP4, I look forward to navigating the path ahead and delivering on the promise of this program for patients and their families.” Mr. MacLean brings more than 35 years of strategic financial leadership in the biotechnology and life sciences industries, with extensive experience supporting the growth of innovative biotechnology companies advancing novel genetic medicines. Most recently, he served as Chief Financial Officer at Avidity Biosciences, joining prior to the company’s 2020 IPO and leading finance and business functions until its acquisition by Novartis in 2026. Prior to Avidity, Mr. MacLean served as Chief Financial...